Over the past five years, AngioDynamics has undertaken a comprehensive repositioning of its business, shifting from a primarily interventional radiology–focused portfolio into broader, higher-growth cardiovascular and oncology device markets. Under CEO James Clemmer’s leadership, the company conducted a rigorous review of its product lines and completed three divestitures to exit lower-growth segments, reallocating resources toward more addressable opportunities. This strategic pivot reflects management’s goal to build a “scientific-based” portfolio capable of delivering sustained revenue growth and improved margins in larger end markets.

Following portfolio realignment, AngioDynamics has introduced several next-generation devices designed to address critical unmet needs in peripheral vascular and oncology interventions. The company highlighted developmental milestones at the J.P. Morgan Healthcare Conference, noting expansion of its precision atherectomy and ablation platforms. Management emphasized plans to leverage its upstate New York manufacturing footprint to ramp production capacity by 20% over the next 12 months, positioning AngioDynamics to capture share in minimally invasive procedures projected to grow at a mid-teens annual rate through 2030.